New England Journal of Medicine APRIL 21, 2021

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Jerald Sadoff, Glenda Gray, An Vandebosch, et al. (ENSEMBLE Study Group)

Bottom Line

The ENSEMBLE trial demonstrated that a single intramuscular dose of the Ad26.COV2.S vaccine was effective in protecting against moderate to severe-critical COVID-19, including hospitalization and death.

Key Findings

1. The vaccine showed a 66.1% efficacy against moderate to severe-critical COVID-19 at least 28 days post-vaccination.

2. Vaccine efficacy against severe-critical COVID-19 reached 85.4% at least 28 days after administration.

3. The vaccine provided protection as early as 14 days after a single dose.

4. A total of 468 symptomatic COVID-19 cases were identified, with 116 in the vaccine group and 348 in the placebo group.

5. The safety profile was generally well-tolerated, with serious adverse events balanced between the vaccine and placebo groups.

Study Design

Design

RCT

Double-Blind

Sample

43,783

Patients

Duration

At least 28 days

Median

Setting

Multicenter, International

Population Adults 18 years of age and older who were at risk for SARS-CoV-2 infection

Intervention Single intramuscular dose of Ad26.COV2.S (5×10^10 viral particles)

Comparator Placebo (saline)

Outcome Vaccine efficacy against moderate to severe-critical COVID-19 at least 14 days and at least 28 days after administration

Study Limitations

• The study was conducted during a period of rapidly evolving SARS-CoV-2 variants, which may affect generalizability.

• The interim analysis focused on short-term efficacy, requiring ongoing monitoring for durability of protection.

• The trial was not powered to detect rare adverse events, such as the later-identified association with thrombosis with thrombocytopenia syndrome.

Clinical Significance

This trial established the utility of a single-dose regimen for COVID-19 vaccination, offering significant logistical advantages for global distribution and public health efforts compared to multi-dose platforms.

Historical Context

The ENSEMBLE trial was a landmark study during the COVID-19 pandemic, providing critical evidence for the emergency use authorization of the Janssen Ad26.COV2.S vaccine, which utilized a non-replicating adenoviral vector technology to combat the spread of SARS-CoV-2.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

The Ad26.COV2.S vaccine utilizes a replication-incompetent adenovirus vector. How does the biological pathway of this vaccine differ from mRNA-based vaccines in terms of how the SARS-CoV-2 spike protein is synthesized within the host cell?

Key Response

Unlike mRNA vaccines (BNT162b2/mRNA-1273) which deliver a lipid-nanoparticle encapsulated mRNA strand directly to the cytoplasm for translation, the Ad26.COV2.S vaccine delivers double-stranded DNA via a viral vector. This DNA must enter the host cell nucleus to be transcribed into mRNA before it can be translated into the spike protein by cytoplasmic ribosomes.

Resident

In the ENSEMBLE trial, the vaccine demonstrated 85% protection against severe-critical COVID-19 but lower efficacy against moderate disease. How should this distinction inform your clinical counseling for a patient concerned about 'breakthrough infections' compared to 'hospitalization risk'?

Key Response

Residents must communicate that while the vaccine may not prevent all symptomatic 'moderate' illness (66% efficacy), its primary clinical value lies in its high efficacy (85%) against the most morbid outcomes including respiratory failure, ICU admission, and death, which are the primary drivers of healthcare utilization and mortality.

Fellow

The ENSEMBLE trial was conducted across diverse geographic regions including South Africa and Brazil. How do the efficacy results against the B.1.351 (Beta) variant observed in this study challenge the traditional reliance on in vitro neutralizing antibody titers as the sole correlate of protection?

Key Response

Despite a significant drop in neutralizing antibody titers against the Beta variant in laboratory assays, the trial still showed high protection against severe disease in South Africa. This suggests that other immune mechanisms, particularly robust CD8+ T-cell responses and non-neutralizing antibody functions (Fc-mediated), play a critical role in preventing severe clinical progression even when neutralization is bypassed.

Attending

When teaching trainees about the Ad26.COV2.S trial results, how do you contextualize the 'single-dose' advantage of this platform against the emerging longitudinal data regarding waning immunity and the need for homologous vs. heterologous boosting?

Key Response

The Janssen vaccine's single-dose regimen offered an immediate public health advantage for hard-to-reach populations and logistical simplicity. However, attendings must highlight that subsequent data (beyond the initial ENSEMBLE report) showed that a heterologous booster (mRNA) following the Janssen primary dose provides a more robust immune response than a second Janssen dose, reflecting an evolution in our understanding of 'prime-boost' strategies.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The ENSEMBLE study used a 'per-protocol' population for its primary efficacy analysis starting at 14 and 28 days post-vaccination. What are the potential biases introduced by this time-lagged exclusion of early cases, and how does it affect the assessment of the vaccine's immediate kinetic response?

Key Response

Excluding cases that occur within the first 14 days post-injection (the 'immature' immune period) can artificially inflate efficacy estimates by ignoring the window where the vaccine has not yet achieved steady-state protection. For PhD-level analysis, this necessitates a complementary 'modified intention-to-treat' (mITT) analysis starting from day 0 to fully understand the onset of protection and real-world impact.

Journal Editor

As a reviewer, if the study authors had not provided the breakdown of efficacy by variant (specifically the South African subset), how would that omission have fundamentally altered the editorial significance and validity of the paper's global conclusions?

Key Response

Without variant-specific data, the aggregate efficacy would mask the significant geographic heterogeneity in performance. A rigorous reviewer would flag that an 'average' efficacy of 66% is misleading if the vaccine performs significantly worse against emerging lineages, which is crucial for determining the global durability of the vaccine candidate.

Guideline Committee

Based on the ENSEMBLE data showing 66% efficacy against moderate-to-severe disease compared to the >90% efficacy reported for mRNA vaccines, how should a national advisory committee (e.g., ACIP) weight the 'preferential recommendation' for mRNA vaccines versus the logistical utility of the Ad26 platform?

Key Response

Guideline committees must balance the high individual-level efficacy of mRNA vaccines against the population-level benefits of a single-dose, refrigerator-stable vaccine. Current ACIP and WHO guidelines generally express a 'preferential recommendation' for mRNA vaccines due to superior efficacy and the lower risk of rare adverse events (like TTS), but retain Janssen as a vital option for patients with contraindications to mRNA or those who would otherwise remain unvaccinated due to access issues.

Clinical Landscape

Noteworthy Related Trials

2020

COVE Trial

n = 30,420 · NEJM

Tested

mRNA-1273 vaccine (Moderna)

Population

Adults at high risk of SARS-CoV-2 infection

Comparator

Placebo

Endpoint

Prevention of symptomatic COVID-19

Key result: The vaccine showed 94.1% efficacy in preventing symptomatic COVID-19 illness.

2021

COV002 and COV003 Trials

n = 23,745 · Lancet

Tested

ChAdOx1 nCoV-19 vaccine (AstraZeneca)

Population

Adults 18 years or older

Comparator

Meningococcal vaccine or saline

Endpoint

Symptomatic COVID-19 infection

Key result: The vaccine showed overall efficacy of 66.7% against symptomatic infection after two doses.

2021

EPIC-HR Trial

n = 2,246 · NEJM

Tested

Nirmatrelvir plus ritonavir

Population

Non-hospitalized adults with mild-to-moderate COVID-19 at high risk for progression

Comparator

Placebo

Endpoint

Hospitalization or death from any cause through day 28

Key result: Treatment reduced the risk of hospitalization or death by 89% compared to placebo.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis